Stay updated on INTRUST: Urelumab/Nivolumab Combo Clinical Trial
Sign up to get notified when there's something new on the INTRUST: Urelumab/Nivolumab Combo Clinical Trial page.

Latest updates to the INTRUST: Urelumab/Nivolumab Combo Clinical Trial page
- Check7 days agoChange DetectedThe clinical trial page is accessible again, showing the study’s treatment plan, eligibility criteria, locations, outcomes, and related publications in place of an error page.SummaryDifference69%

- Check14 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check21 days agoChange DetectedA sitewide banner announces NIH website updates and explains the transition from the term “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision changed from v3.7.1 to v3.7.2, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the full study record with a minimal message. As a result, core trial details and history sections are no longer visible, blocking access to the study information.SummaryDifference20%

Stay in the know with updates to INTRUST: Urelumab/Nivolumab Combo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INTRUST: Urelumab/Nivolumab Combo Clinical Trial page.